drugset / Trial / NCT05439356

Colchicine in High-risk Patients With Acute Minor-to-moderate Ischemic Stroke or Transient Ischemic Attack (CHANCE-3)

NCT05439356

Phase 3 Completed 8343 enrolled Beijing Tiantan Hospital
RandomizedParallel-groupQuadruple-blindPrevention

Summary

This study is a multicentre, randomized, double-blind, placebo-controlled, investigator-sponsored study that aims to investigate the efficacy of colchicine in preventing recurrent stroke in the patients with acute minor-to-moderate ischemic stroke or TIA and a hsCRP level of ≥2mg/L.

Timeline

Start
2022-08-11
Primary completion
2023-07-13
Completion
2024-04-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Colchicine Small molecule 0.5 mg Oral